UBS upgraded MCX to Buy from Neutral and raised its target price to Rs 3,800, citing attractive valuations, resilient trading volumes and positive regulatory developments. The brokerage also raised its FY27-FY29 EPS estimates by 4%-9%, while expecting strong commodity volatility and operating leverage to support earnings growth.
